Pengaruh Lama Penggunaan Kombinasi ARV (TDF+3TC+EFV) terhadap Jumlah Sel CD4+ Pasien HIV/AIDS
Abstract
Human Immunodeficiency Virus (HIV) merupakan penyakit yang menyerang sistem imun manusia yaitu sel CD4+ dan dapat berkembang menjadi Acquired Immune Deficiency Syndrome (AIDS) sebagai lanjutan dari penyakit HIV. Prevalensi terjadinya HIV/AIDS di Tulungagung adalah yang terbanyak di Jawa Timur. Data di RSUD Dr. Iskak Tulungagung sampai tahun 2018 menunjukkan jumlah pasien HIV/AIDS sebanyak 2.082 orang dan yang menjalani pengobatan sebanyak 588 orang. Penelitian dilakukan untuk mengetahui pengaruh lama penggunaan kombinasi obat ARV (TDF+3TC+EFV) selama 6–42 bulan terhadap jumlah sel CD4+. Pengambilan data penelitian dilakukan di unit rekam medis RSUD Dr. Iskak Tulungagung pada bulan Agustus–Oktober 2019. Metode yang digunakan pada penelitian ini adalah observasional potong lintang dengan pengambilan data secara retrospektif. Subjek yang memenuhi kriteria inklusi sebanyak 86 pasien HIV/AIDS. Hasil penelitian dengan uji korelasi Pearson menunjukkan bahwa semakin lama pengobatan kombinasi ARV maka jumlah sel CD4+ juga semakin meningkat (p<0,001; r= +0,394). Berdasarkan uji one-way ANOVA, diketahui bahwa peningkatan CD4+ yang signifikan mulai terlihat dengan pengobatan kombinasi ARV minimal selama 18 bulan (p<0,001).
Kata kunci: Antiretroviral, CD4+, HIV/AIDS, Tenofovir+Lamivudin+Efavirenz (TDF+3TC+EFV)
The Long-term Effect of Using ARV Combinations (TDF+3TC+EFV) on CD4+ Cell Counts of HIV/AIDS Patients
Abstract
Human immunodeficiency virus (HIV) is known to attack the human immune system, i.e., CD4 + cells and develops into Acquired Immune Deficiency Syndrome (AIDS) as a continuation of the disease. Furthermore, the prevalence of HIV/AIDS in Tulungagung is recorded as the highest in East Java. The data collected from Dr. Iskak Tulungagung Hospital until 2018, showed that there were 2,082 patients suffering from this disease while 588 of them received treatment. Therefore, this study aims to determine the effect and the use duration of ARV medicines (TDF+3TC+EFV) for 6–42 months on the CD4+ cell counts. The research data was collected from the medical record unit at Dr. Iskak Tulungagung Hospital from August–October 2019. The method used was a cross sectional design and observation retrospective technique. Moreover, 86 HIV/AIDS patients met the inclusion criteria. The results of Pearson correlation test showed that the longer the ARV treatment, the higher the number of CD4+ cells (p<0.001; r= +0.394). From one-way ANOVA test, a significant increase in CD4+ cell was also observed with ARV treatment for at least 18 months (p<0.001).
Keywords: Antiretroviral, CD4+, HIV/AIDS, Tenofovir+Lamivudine+Efavirenz (TDF+3TC+EFV)
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Aptriani R, Fridayenti, Barus A. Gambaran jumlah CD4 pada pasien HIV/AIDS di klinik VCT RSUD Arifin Achmad Provinsi Riau periode Januari-Desember 2013. Jom FK. 2014;1(2):1–12.
Dinas Kesehatan Jawa Timur. Profil Kesehatan Provinsi Jawa Timur Tahun 2016. Surabaya: Dinas Kesehatan Provinsi Jawa Timur; 2016.
Dinas Kesehatan Tulungagung. Profil Kesehatan Tahun 2017. Tulungagung: Dinas Kesehatan Kabupaten Tulungagung; 2017.
Sistem Informasi HIV/AIDS (SIHA). Laporan Situasi Perkembangan HIV-AIDS & PIMS di Indonesia April–Juni 2018. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit; 2018.
Yuliandra Y, Nosa US, Raveinal, Almasdy D. Terapi antiretroviral pada pasien HIV/AIDS di RSUP. Dr. M. Djamil Padang: Kajian sosiodemografi dan evaluasi obat. J Sains Farmasi Klinis. 2017;4(1):1–8. doi: 10.29208/jsfk.2017.4.1.173
Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection 2014 recommendations of the International Antiviral Society-USA panel. J Am Med Assoc. 2014;312(4):410–25. doi: 10.1001/jama.2014.8722
Akanbi MO, Scarci K, Taiwo B, Murphy RL. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother. 2012;13(1):65–79. doi: 10.1517/14656566.2012.642865
Avihingsanon A, Maek-A-Nantawat W, Gatechompol S, Sapsirisavat V, Thiansanguankul W, Sophonphan J, et al. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. Int J Infect Dis. 2017;61(2017):89–96. doi: 10.1016/j.ijid.2017.06.009
Meloni ST, Chang CA, Eisen G, Jolayemi T, Banigbe B, Okonkwo PI, et al. Long-term outcomes on antiretroviral therapy in a large scale-up program in Nigeria. PLoS ONE. 2016;11(10):e0164030. doi: 10.1371/journal.pone.0164030
Ahn JY, Boettiger D, Law M, Kumarasamy N, Yunihastuti E, Chaiwarith R, et al. Effects of CD4 monitoring frequency on clinical endpoints in clinically stable HIV-infected patients with viral suppression. J Acquir Immune Defic Syndr. 2015;69(3):e85–92. doi: 10.1097/QAI.0000000000000634
Wahyudi ST. Statistika Ekonomi: konsep, teori dan penerapan. Malang: UB Press; 2017.
Azza A. Beban perempuan penderita HIV/AIDS dalam perspektif gender. J Ners. 2010;5(2):118–26.
Adimora AA, Ramirez C, Auerbach JD, Aral SO, Hodder S, Wingood G, et al. Preventing HIV infection in women. J Acquir Immune Defic Syndr. 2013;63(02):S168–73. doi: 10.1097/QAI.0b013e318298a166
Dewi DMSK, Wulandari LPL, Karmaya INM. Women’s vulnerability to STIs and HIV transmission: High risk sexual behavior in Denpasar City. Public Health Prev Med Archive. 2013;1(1):13–8.
Kementerian Kesehatan Republik Indonesia. Perkembangan HIV-AIDS & PIMS di Indonesia Januari–Desember 2018. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit; 2018.
Hegdahl HK, Fylkesnes KM, Sandoy IF. Sex differences in HIV prevalence persist over time: Evidence from 18 countries in Sub-Saharan Africa. PLoS ONE. 2016;11(2):e0148502. doi: 10.1371/journal.pone.0148502
Ladyani F, Kiristianingsih A. Hubungan antara jumlah CD4 pada pasien yang terinfeksi HIV/AIDS dengan infeksi oportunistik di Rumah Sakit Umum Abdul Moeloek Bandar Lampung tahun 2016. J Kedokt Unila. 2019;3(1):34–41. doi: 10.2 3960/jk%20unila.v3i1.2201
World Health Organization . Consolidated guidelines antiretroviral drug as for treating and preventing HIV infection. London: World Health Organization; 2013.
Severe P, Juste MA, Alex A, Ludger E, Claudel M, Sandra A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–65. doi: 10.1056/NEJMoa0910370
Sucipto KW, Gani AA, Abubakar A, Zufry H, Debbyousha M. Proceeding Book The 5th Aceh Internal Medicine Symposia 2014; 2014 Maret 6–8; Banda Aceh, Indonesia. Indonesia: Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Syiah Kuala/RSUD Dr. Zainoel Abidin; 2014.
DOI: https://doi.org/10.15416/ijcp.2020.9.3.219
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
